Citations

Clear

7552 citation(s) found for "Ho, Matthew".

Pipeline for uncoilable or failed aneurysms: 3-year follow-up results
Becske, Tibor , Potts, Matthew B. , Shapiro, Maksim , Kallmes, David F. , Brinjikji, Waleed , Saatçi, Işıl , McDougall, Cameron G. , Szikora, István , Moran, Christopher J. , Woo, Henry H. , Berez, Aaron L., Cher, Daniel , Siddiqui, Adnan H. , Albuquerque, Felipe C. , Berentei, Zsolt, Marosföi, Miklós , Cekirge, Saruhan H., Nelson, Peter K. , Lanzino, Giuseppe , Lopes, Demetrius K. , Levy, Elad I. , Fiorella, David , Siddiqui, Adnan H , Szikora, Istvan

Mayo Clinic

Journal of Neurosurgery | October 14, 2016 | Volume: 127 | Issue: 1 | Pages: 81-88

10.3171/2015.6.jns15311 | PMID 27739944 Get It

OBJECTIVEThe long-term effectiveness of endovascular treatment of large and giant wide-neck aneurysms using traditional endovascular techniques has been disappointing, with high recanalization and re-treatment rates. Flow diversion with the Pipeline Embolization Device (PED) has been recently used as a stand-alone therapy for complex aneurysms, showing significant improvement in effectiveness while demonstrating a similar safety profile to stent-supported coil treatment. However, relatively little is known about its long-term safety and effectiveness. Here the authors report on the 3-year safety and effectiveness of flow diversion with the PED in a prospective cohort of patients with large and giant internal carotid artery aneurysms enrolled in the Pipeline for Uncoilable or Failed Aneurysms (PUFS) trial.METHODSThe PUFS trial is a prospective study of 107 patients with 109 aneurysms treated with the PED. Primary effectiveness and safety end points were demonstrated based on independently monitored 180-day clinical and angiographic data. Patients were enrolled in a long-term follow-up protocol including 1-, 3-, and 5-year clinical and imaging follow-up. In this paper, the authors report the midstudy (3-year) effectiveness and safety data.RESULTSAt 3 years posttreatment, 74 subjects with 76 aneurysms underwent catheter angiography as required per protocol. Overall, complete angiographic aneurysm occlusion was observed in 71 of these 76 aneurysms (93.4% cure rate). Five aneurysms were re-treated, using either coils or additional PEDs, for failure to occlude, and 3 of these 5 were cured by the 3-year follow-up. Angiographic cure with one or two treatments of Pipeline embolization alone was therefore achieved in 92.1%. No recanalization of a previously completely occluded aneurysm was noted on the 3-year angiograms. There were 3 (2.6%) delayed device- or aneurysm-related serious adverse events, none of which led to permanent neurological sequelae. No major or minor late-onset hemorrhagic or ischemic cerebrovascular events or neurological deaths were observed in the 6-month through 3-year posttreatment period. Among 103 surviving patients, 85 underwent functional outcome assessment in which modified Rankin Scale scores of 0–1 were demonstrated in 80 subjects.CONCLUSIONSPipeline embolization is safe and effective in the treatment of complex large and giant aneurysms of the intracranial internal carotid artery. Unlike more traditional endovascular treatments, flow diversion results in progressive vascular remodeling that leads to complete aneurysm obliteration over longer-term follow-up without delayed aneurysm recanalization and/or growth.Clinical trial registration no.: NCT00777088 (clinicaltrials.gov)
Varying Degrees of Temporoparietal Hypometabolism on FDG-PET Reveal Amyloid-Positive Logopenic Primary Progressive Aphasia is not a Homogeneous Clinical Entity
Krishnan, K. Ranga, Whitwell, Jennifer L. , Butts, Alissa M. , Senjem, Matthew L. , Spychalla, Anthony J., Jack, Clifford R. , Lowe, Val J. , Josephs, Keith A. , Krishnan, Kamini, Strand, Edythe A. , Machulda, Mary M. , Duffy, Joseph R. , Jack, Clifford R , Senjem, Matthew L

Mayo Clinic

Journal of Alzheimer's Disease | October 14, 2016 | Volume: 55 | Issue: 3 | Pages: 1019-1029

10.3233/jad-160614 | PMID 27802232 Get It

Risk of progressive hearing loss in untreated superior semicircular canal dehiscence
Patel, Neil S. , Hunter, Jacob B. , O’Connell, Brendan P., Bertrand, Natalie M., Wanna, George B. , Carlson, Matthew L. , Hunter, Jacob B

Mayo Clinic

The Laryngoscope | October 14, 2016 | Volume: 127 | Issue: 5 | Pages: 1181-1186

10.1002/lary.26322 | PMID 27739592 Get It

ObjectivePatients with incidental or minimally symptomatic superior semicircular canal dehiscence (SSCD) are usually observed, without surgical repair. However, it remains unknown whether a labyrinthine fistula of the superior semicircular canal is associated with progressive conductive or sensorineural hearing loss over time.Study DesignRetrospective review at two tertiary care academic referral centers.MethodsAdults analyzed were diagnosed with SSCD by high‐resolution temporal bone computed tomography and vestibular evoked myogenic potential testing and observed with a minimum of two sequential audiograms. Patients with other potential causes of hearing impairment were excluded.ResultsA total of 40 ears in 30 adult patients (median age: 59 years; 63% female) were analyzed. Median audiometric follow‐up was 23 months (range 1–136 months). None experienced a sudden hearing loss over the follow‐up period. In patients with audiometric follow‐up of at least 20 months (median 34 months), the median change in air‐conduction pure tone average and air–bone gap was 0.9 decibels (dB) per year (interquartile range [IQR] 0–2.1) and 0.7 dB per year (IQR 0–2.0), respectively. Speech discrimination scores did not differ when comparing median initial (100%) and median final (98%) scores (P = 0.77). There was no statistically significant change in bone‐conduction thresholds at 0.5, 1, 2, and 4 kHz over the period of observation.ConclusionThe risk of progressive hearing loss with observed SSCD is low during short‐ and intermediate‐term follow‐up. Further studies are necessary to determine whether late hearing loss occurs. Such information may be critical toward patient counseling regarding the need for and timing of surgery.Level of Evidence4. Laryngoscope, 127:1181–1186, 2017
Early outcomes after cochlear implantation for adults and children with unilateral hearing loss
Sladen, Douglas P. , Carlson, Matthew L. , Dowling, Brittany P., Olund, Amy P., Teece, Kathryn, DeJong, Melissa D., Breneman, Alyce, Peterson, Ann M. , Beatty, Charles W., Neff, Brian A., Driscoll, Colin L. W., Teece, Katherine , Peterson, Ann, Driscoll, Colin L.

Mayo Clinic

The Laryngoscope | October 13, 2016 | Volume: 127 | Issue: 7 | Pages: 1683-1688

10.1002/lary.26337 | PMID 27730647 Get It

Objectives/HypothesisThis study was designed to examine speech recognition and self‐perceived health‐related quality of life (HRQoL) received from cochlear implantation among a cohort of adults and children with a short duration of unilateral hearing loss greater than 6 months, but less than 2 years.Study DesignSingle‐subject repeated measures prospective study.MethodsThis study assessed changes in speech recognition and self‐perceived quality of life by prospectively analyzing data at the preoperative evaluation and at the 3‐month and 6‐month postactivation intervals. Measurement tools included Medical Outcomes Study Questionnaire Short Form 36, Nijmegen Cochlear Implant Questionnaire, Speech Spatial and Qualities of Hearing–Comparative, and speech recognition measures in quiet and in noise.ResultsResults indicated significant improvement in speech recognition, both in quiet and noise. Quality‐of‐life measures showed a significant increase in self‐perceived benefit with disease‐specific instruments, but remained constant with a generic HRQoL instrument.ConclusionsCochlear implantation was a successful intervention for improved hearing in quiet and noise, and a self‐perceived benefit for this group of adults and children with a short duration of unilateral hearing loss.Level of Evidence4 Laryngoscope, 127:1683–1688, 2017
Hemifacial Spasm Secondary to Parotid Pleomorphic Adenoma With Stylomastoid Foramen Extension
Martin, Eliot J., Carlson, Matthew L. , Moore, Eric J. , Jackson, Ryan S.

Mayo Clinic

Otology & Neurotology | October 13, 2016 | Volume: 38 | Issue: 1 | Pages: 129-132

10.1097/mao.0000000000001256 | PMID 27755360 Get It

Objective: To report hemifacial spasm (HFS) as a rare presenting symptom of a benign parotid neoplasm involving the stylomastoid foramen. Methods: Case report with literature review. Results: An 18-year-old woman presented with a 1-year history of a progressively enlarging right infra-auricular mass with new onset ipsilateral severe HFS. Clinical vetting unveiled a palpable 2 cm, firm, minimally mobile mass medial to the angle of the mandible. Imaging revealed a heterogeneous intraparotid mass with tumor extension into the stylomastoid foramen. Diagnostic consideration was given to neurogenic tumors and neoplasms of parotid origin. The patient ultimately underwent superficial parotidectomy and the tumor was found superficial and extrinsic to the proximal facial nerve trunk but extended into the stylomastoid foramen. The tumor was removed after performing mastoidectomy with mastoid segment facial nerve decompression. Frozen section pathology was consistent with pleomorphic adenoma. Postoperatively the patient had normal facial nerve function with immediate and complete resolution of HFS. To date there are only three other published reports of benign parotid tumors presenting with HFS and this is the first illustrating intratemporal tumor extension. Conclusions: HFS is a rare presenting symptom associated with benign parotid neoplasms with scarce documentation in the literature. In this index case, tumor extirpation with mastoid segment facial nerve decompression provided immediate and durable resolution of symptoms.
Glenoid Bone-Grafting in Revision to a Reverse Total Shoulder Arthroplasty: Surgical Technique
Wagner, Eric R. , Elhassan, Bassem T. , Sperling, John W. , Cofield, Robert H. , Wagner, Eric, Sanchez-Sotelo, Joaquin, Houdek, Matthew T. , Sánchez‐Sotelo, Joaquín , Wagner, Eric R

Mayo Clinic

JBJS Essential Surgical Techniques | October 12, 2016 | Volume: 6 | Issue: 4 | Pages: e35

10.2106/jbjs.st.15.00023 | PMID 30233928 Get It

Safety of Local Intracutaneous Lidocaine Anesthesia Used by Dermatologic Surgeons for Skin Cancer Excision and Postcancer Reconstruction: Quantification of Standard Injection Volumes and Adverse Event Rates
Alam, Murad , Schaeffer, Matthew, Geisler, Amelia, Poon, Emily , Fosko, Scott W. , Srivastava, Divya, Alam, Murad

Mayo Clinic

Dermatologic Surgery | October 12, 2016 | Volume: 42 | Issue: 12 | Pages: 1320-1324

10.1097/dss.0000000000000907 | PMID 27893492 Get It

BACKGROUND Intracutaneous lidocaine is used for anesthesia in dermatologic surgery for skin cancer excision and repair with exceedingly low incidence of reported adverse events. OBJECTIVE To measure (1) the quantity of lidocaine typically used for facial skin cancer excision and reconstruction; and (2) the frequency and character of associated adverse events. METHODS Survey study of dermatologic surgeons with longitudinal reporting. Reported practice during 10 business days: (1) mean volume of 1% lidocaine per skin cancer excision; (2) maximum per excision; (3) mean per reconstruction; and (4) maximum per reconstruction. RESULTS A total of 437 of 1,175 subjects contacted (37.2%) responded. Mean per excision was 3.44 mL (SD: 2.97), and reconstruction 11.70 mL (10.14). Maximum per excision was 6.54 mL (4.23), and reconstruction was 15.85 mL (10.39). No cases of lidocaine toxicity were reported, diagnosed, or treated. Incidence of adverse events possibly anesthesia related was >0.15%, with most (0.13%) being mild cases of dizziness, drowsiness, or lightheadedness from epinephrine tachycardia. CONCLUSION Toxicity associated with local anesthesia other than lidocaine was not studied. Volumes of lidocaine in skin cancer excision and repair are modest and within safe limits. Lidocaine toxicity is exceedingly rare to entirely absent. For comparable indications, lidocaine is safer than conscious sedation or general anesthesia.
Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy
Goss, Paul E. , Shepherd, Lois E. , Chapman, J. W. , Chen, Bingshu E. , Kubo, Michiaki , Furukawa, Yoichi , Momozawa, Yukihide , Stearns, Vered , Barman, Poulami , Weinshilboum, Richard M. , Kalari, Krishna R. , Wang, Liewei , Xie, Fang , Ingle, James N. , Xie, Fang , Ellis, Matthew J. , Chapman, Judith‐Anne W. , Pritchard, Kathleen I. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M. , Stearns, Vered , Chen, Bingshu E , Kalari, Krishna R

Mayo Clinic

Cancer Research | October 11, 2016 | Volume: 76 | Issue: 23 | Pages: 7012-7023

10.1158/0008-5472.can-16-1371 | PMID 27758888 Get It

Abstract Genetic risks in breast cancer remain only partly understood. Here, we report the results of a genome-wide association study of germline DNA from 4,658 women, including 252 women experiencing a breast cancer recurrence, who were entered on the MA.27 adjuvant trial comparing the aromatase inhibitors (AI) anastrozole and exemestane. Single-nucleotide polymorphisms (SNP) of top significance were identified in the gene encoding MIR2052HG, a long noncoding RNA of unknown function. Heterozygous or homozygous individuals for variant alleles exhibited a ∼40% or ∼63% decrease, respectively, in the hazard of breast cancer recurrence relative to homozygous wild-type individuals. Functional genomic studies in lymphoblastoid cell lines and ERα-positive breast cancer cell lines showed that expression from MIR2052HG and the ESR1 gene encoding estrogen receptor-α (ERα) was induced by estrogen and AI in a SNP-dependent manner. Variant SNP genotypes exhibited increased ERα binding to estrogen response elements, relative to wild-type genotypes, a pattern that was reversed by AI treatment. Further, variant SNPs were associated with lower expression of MIR2052HG and ERα. RNAi-mediated silencing of MIR2052HG in breast cancer cell lines decreased ERα expression, cell proliferation, and anchorage-independent colony formation. Mechanistic investigations revealed that MIR2052HG sustained ERα levels both by promoting AKT/FOXO3-mediated ESR1 transcription and by limiting ubiquitin-mediated, proteasome-dependent degradation of ERα. Taken together, our results define MIR2052HS as a functionally polymorphic gene that affects risks of breast cancer recurrence in women treated with AI. More broadly, our results offer a pharmacogenomic basis to understand differences in the response of breast cancer patients to AI therapy. Cancer Res; 76(23); 7012–23. ©2016 AACR.
Urinary collecting system invasion is associated with poor survival in patients with clear‐cell renal cell carcinoma
Bailey, George C., Boorjian, Stephen A. , Ziegelmann, Matthew , Westerman, Mary E. , Lohse, Christine M. , Leibovich, Bradley C. , Cheville, John C. , Thompson, R. Houston, Ziegelmann, Matthew J, Westerman, Mary E

Mayo Clinic

BJU International | October 11, 2016 | Volume: 119 | Issue: 4 | Pages: 585-590

10.1111/bju.13669 | PMID 27696652 Get It

Objectives To evaluate the prognostic significance of urinary collecting system invasion ( UCSI ) in a large series of patients with clear‐cell renal cell carcinoma ( RCC ). Materials and Methods Patients with clear‐cell RCC treated with nephrectomy between 2001 and 2010 were reviewed from a prospectively maintained registry. One urological pathologist re‐reviewed all slides. Cancer‐specific survival was estimated using the Kaplan–Meier method, and associations of UCSI with death from RCC were evaluated using Cox models. Results Of the 859 patients with clear‐cell RCC , 58 (6.8%) had UCSI . At last follow‐up, 310 patients had died from RCC at a median of 1.8 years after surgery. The median follow‐up for patients alive at last follow‐up was 8.2 years. The estimated cancer‐specific survival at 10 years after surgery for patients with UCSI was 17%, compared with 60% for patients without UCSI ( P < 0.001). In a multivariable model, UCSI remained independently associated with an increased risk of death from RCC (hazard ratio 1.5; P = 0.018). Further, among patients with pT 3 RCC , those with USCI had survival outcomes similar to those of patients with pT 4 RCC. Conclusions Collecting system invasion is associated with poor prognosis among patients with clear‐cell RCC . If validated, consideration should be given to including UCSI in future staging systems.
Editorial Comment
Tollefson, Matthew K.

Mayo Clinic

Journal of Urology | October 8, 2016 | Volume: 197 | Issue: 1 | Pages: 82-82

10.1016/j.juro.2016.07.104 | PMID 27717688 Get It